日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Concomitant use of miglitol and mitiglinide as initial combination therapy in type 2 diabetes mellitus

米格列醇与米格列奈联合使用作为 2 型糖尿病的初始联合治疗

Fuminori Tatsumi, Mitsuru Hashiramoto, Hidenori Hirukawa, Tomohiko Kimura, Masashi Shimoda, Kazuhito Tawaramoto, Yukiko Kanda-Kimura, Takatoshi Anno, Fumiko Kawasaki, Tomoatsu Mune, Michihiro Matsuki, Kohei Kaku

Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study)

阿折地平(而非氨氯地平)可降低 2 型糖尿病患者的尿白蛋白排泄量和颈动脉粥样硬化:使用奥美沙坦和阿折地平控制 2 型糖尿病患者的血压(BOAT2 研究)

Kazuhito Tawaramoto, Hideaki Kaneto, Mitsuru Hashiramoto, Fumiko Kawasaki, Fuminori Tatsumi, Masashi Shimoda, Shinji Kamei, Michihiro Matsuki, Tomoatsu Mune, Kohei Kaku

The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3

-420位点的抵抗素单核苷酸多态性G/G基因型通过Sp1/3特异性结合诱导启动子活性,从而增加2型糖尿病的易感性。

Haruhiko Osawa,Kazuya Yamada, Hiroshi Onuma, Akiko Murakami, Masaaki Ochi, Hiroko Kawata, Tatsuya Nishimiya, Toshiyuki Niiya, Ikki Shimizu, Wataru Nishida, Mitsuru Hashiramoto, Azuma Kanatsuka, Yasuhisa Fujii, Jun Ohashi, Hideichi Makino